CERS - Cerus Faces Pipeline Of Calamities Going Into 2021
- In spite of common misconception, Cerus is not among the few companies to profit in treatment or prevention of the COVID-19 virus.
- The implementation of the INTERCEPT Blood System in the United States would serve to further deplete the critically low present blood supply.
- Scores of complaints emerged following issuance of industry guidance for blood transfusion safety by the FDA. Blood centers have conducted costly experiments in hopes of preserving the U.S. blood supply.
- Prevention of transfusion related deaths - a phenomenon less common than death by lightning strike - does nothing to justify the implied detriment to an endangered blood supply Cerus.
For further details see:
Cerus Faces Pipeline Of Calamities Going Into 2021